Given these clinical implications, the National Comprehensive Cancer Network and European LeukemiaNet guidelines recommend routine molecular testing for FLT3 mutations in all AML patients as part of the diagnostic workup [11,12] and for consideration in clinical trial enrollment [11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.